Insights

Innovative Technology Platform TheraVectys leverages proprietary lentiviral vector technology, positioning it as a leader in advanced immunotherapy solutions. This offers opportunities to collaborate on novel vaccine delivery systems and targeted immune response technologies.

Strategic R&D Collaborations The company maintains an exclusive joint laboratory with the Institut Pasteur, indicating a strong foundation for joint research projects and co-development opportunities in cancer and infectious disease therapies.

Recent Funding Momentum With a recent $20 million funding round, TheraVectys is positioned for expansion of its pipeline and clinical programs, presenting potential opportunities to supply research, technology licensing, or partnership engagement.

Market Focus and Pipeline TheraVectys is actively developing vaccine candidates targeting unmet medical needs in oncology and infectious diseases, opening avenues for partners interested in early-stage biotech licensing or distribution agreements.

Global Presence and Capabilities Based in Paris and the USA with a focused biotech team, the company offers a strategic geographical footprint for expanding collaborations in North America and Europe, especially for companies seeking innovative immunotherapies.

THERAVECTYS Tech Stack

THERAVECTYS uses 8 technology products and services including jsDelivr, MySQL, Font Awesome, and more. Explore THERAVECTYS's tech stack below.

  • jsDelivr
    Content Delivery Network
  • MySQL
    Database
  • Font Awesome
    Font Scripts
  • yepnope.js
    Javascript Frameworks
  • jQuery Migrate
    Javascript Libraries
  • SWFObject
    Miscellaneous
  • Windows Server
    Operating Systems
  • FitVids.js
    Web Tools And Plugins

THERAVECTYS's Email Address Formats

THERAVECTYS uses at least 1 format(s):
THERAVECTYS Email FormatsExamplePercentage
FLast@theravectys.comJDoe@theravectys.com
44%
First.Last@theravectys.comJohn.Doe@theravectys.com
11%
FMiddleLast@theravectys.comJMichaelDoe@theravectys.com
1%
FLast@theravectys.comJDoe@theravectys.com
44%

Frequently Asked Questions

What is THERAVECTYS's phone number?

Minus sign iconPlus sign icon
You can contact THERAVECTYS's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is THERAVECTYS's official website and social media links?

Minus sign iconPlus sign icon
THERAVECTYS's official website is theravectys.com and has social profiles on LinkedInCrunchbase.

What is THERAVECTYS's SIC code NAICS code?

Minus sign iconPlus sign icon
THERAVECTYS's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does THERAVECTYS have currently?

Minus sign iconPlus sign icon
As of December 2025, THERAVECTYS has approximately 18 employees across 3 continents, including EuropeAsiaNorth America. Key team members include Chief Representative: A. H.Trilingual Executive Assistant To Ceo: J. L.Trilingual Executive Assistant To CEO: J. L.. Explore THERAVECTYS's employee directory with LeadIQ.

What industry does THERAVECTYS belong to?

Minus sign iconPlus sign icon
THERAVECTYS operates in the Biotechnology Research industry.

What technology does THERAVECTYS use?

Minus sign iconPlus sign icon
THERAVECTYS's tech stack includes jsDelivrMySQLFont Awesomeyepnope.jsjQuery MigrateSWFObjectWindows ServerFitVids.js.

What is THERAVECTYS's email format?

Minus sign iconPlus sign icon
THERAVECTYS's email format typically follows the pattern of FLast@theravectys.com. Find more THERAVECTYS email formats with LeadIQ.

How much funding has THERAVECTYS raised to date?

Minus sign iconPlus sign icon
As of December 2025, THERAVECTYS has raised $20M in funding. The last funding round occurred on Feb 08, 2021 for $20M.

When was THERAVECTYS founded?

Minus sign iconPlus sign icon
THERAVECTYS was founded in 2005.

THERAVECTYS

Biotechnology ResearchÎle-de-france, France11-50 Employees

Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau.

TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs.

By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases.

Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective transfection mechanism to elicit a potent and targeted immune response previously unseen.

Section iconCompany Overview

Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2005
Employees
11-50

Section iconFunding & Financials

  • $20M

    THERAVECTYS has raised a total of $20M of funding over 4 rounds. Their latest funding round was raised on Feb 08, 2021 in the amount of $20M.

  • $1M

    THERAVECTYS's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $20M

    THERAVECTYS has raised a total of $20M of funding over 4 rounds. Their latest funding round was raised on Feb 08, 2021 in the amount of $20M.

  • $1M

    THERAVECTYS's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.